샘플 요청 목록

 카트 문의
시장보고서
상품코드
1790296

세계의 동물용 항감염제 시장 규모, 점유율, 동향 분석 보고서 : 동물 유형별, 제품별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Veterinary Anti-infectives Market Size, Share & Trends Analysis Report By Animal Type, By Product (Antimicrobials, Antifungals, Antivirals), By Route Of Administration, By Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

동물용 항감염제 시장 개요

세계 동물용 항감염제 시장은 2024년 82억 6,000만 달러로 평가되었습니다. 2033년에는 143억 7,000만 달러에 달하고, 2025-2033년 연평균 6.5% 성장할 것으로 예측됩니다. 시장을 견인할 것으로 예상되는 주요 요인으로는 동물 감염증 증가, 연구 이니셔티브 개발, 신중한 항생제 사용 촉진, 규제 승인 증가, 인공지능(AI) 적용 확대 등이 있습니다.

가장 중요한 촉진요인 중 하나는 수의학 분야에서 인공지능(AI)의 통합이 진행되고 있다는 점입니다. 교육 기관, 동물 복지 단체, 영리 기업은 AI를 도입하여 임상 의사 결정을 간소화하고, 질병을 조기에 발견하고, 치료 격차를 파악하고, 동물용 의약품의 발견을 가속화하기 위해 AI를 채택하고 있습니다. AI는 또한 발병 모니터링에서 예측 모델링의 가능성을 제공하고, 항균제 내성(AMR)에 대한 우려가 높아지는 가운데 항감염제 사용을 간소화하는 데 도움이 될 수 있습니다.

또 다른 중요한 요인은 반려동물과 가축의 전염병이 전 세계적으로 유행하고 있다는 점입니다. 예를 들어, 주요 유제품 생산국인 인도에서는 2023년 럼피 피부병(Lumpy Skin Disease)이 대유행하여 295만 마리의 소가 감염되었고, 15개 주에서 15만 5,000명 이상이 사망했습니다. 마찬가지로 세계 최고의 쇠고기 생산국인 미국에서도 최근 소에서 고병원성 조류인플루엔자(HPAI)가 발생하여 2024년 5월 현재 38개 주에서 250개 이상의 쇠고기 샘플이 양성반응을 보였습니다. 남아공은 또한 계란 생산량이 30% 감소하고 HPAI로 인해 2023년까지 100만 마리 이상의 가금류를 도태시켜야 했습니다. 이러한 질병의 발생은 효과적인 항감염 치료제에 대한 수요를 직접적으로 증가시키고 있습니다.

항균제 내성(AMR) 증가도 시장을 형성하고 있으며, 규제 당국의 엄격한 모니터링을 촉구하고 있습니다. 2025년 6월, 인도 중앙의약품표준관리기구(CDSCO)는 가축의 항생제 사용을 모니터링하기 위한 전국적인 노력을 시작했습니다. CDSCO는 항생제 오남용과 남용을 막기 위해 부처 간 협력 체계를 구축하고, AMU(항균제 사용량) 데이터 보고를 의무화했습니다.

집중적인 연구 개발 및 산업 협력이 이러한 규제 개발을 뒷받침하고 있습니다. 2024년 3월, Zoetis는 Blacksmith Medicines와 협력하여 약제 내성 균주를 선택적으로 표적화하여 내성균을 회피하는 새로운 항생제를 개발했습니다. 마찬가지로, 텍사스 주 수의사가 발견한 소에 대한 조류 인플루엔자의 인수공통전염병과 같은 발견은 가축 질병 관리의 치료 혁신에 새로운 길을 열어줍니다.

또한, 제네릭 의약품과 부가가치가 높은 동물용의약품 증가로 시장 접근성이 확대되고 있습니다. Access VetMed의 2024년 유럽 시장 조사에 따르면, 제네릭 의약품은 동물용 의약품 허가의 약 50%를 차지하며, 항감염증 및 항기생충제에서 큰 견인차 역할을 하고 있습니다. EU 규정 2019/6과 같은 규제 부담, 특히 중소기업에 대한 부담에도 불구하고, 이 부문은 특히 반려동물 제품 및 대체 투여 경로에서 계속 성장하고 있습니다.

전반적으로 감염병 발생 증가, 항균제 사용에 대한 규제 강화, AI와 같은 기술 혁신, 연구개발 및 제네릭 의약품에 대한 투자 증가는 동물용 항감염제 시장을 크게 견인하고 있습니다. 이러한 힘은 현재의 치료 수요를 충족시키고, 동물용 항균제 치료의 장기적인 지속가능성과 유효성을 보장할 것으로 기대됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 동물용 항감염제 시장 변동 동향과 전망

  • 시장 계통 전망
    • 상위 시장
    • 보조 시장
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 시장 기회 분석
    • 시장이 해결해야 할 과제 분석
  • 동물용 항감염제 시장 분석 툴
    • 산업 분석 - Porter의 Five Forces 분석
    • PESTEL 분석
    • 주요 국가의 규제 구조
    • 주요 국가별, 주요종에 의한 동물 추정 개체수(2021-2023년)
    • 주요 감염증 만연 상황(주요 유형별, 주요 국가별, 2024년)
    • COVID-19의 영향 분석

제4장 동물용 항감염제 시장 : 동물 유형별, 추정 및 동향 분석

  • 부문 대시보드
  • 동물용 항감염제 시장 : 동물 유형 변동 분석
  • 동물용 항감염제 시장 규모와 동향 분석(동물 유형별, 2021-2033년)
  • 가축
    • 가금류
    • 돼지
    • 소
    • 양 및 염소
    • 어류
    • 기타
  • 반려동물
    • 개
    • 고양이
    • 기타

제5장 동물용 항감염제 시장 : 제품별, 추정 및 동향 분석

  • 부문 대시보드
  • 동물용 항감염제 시장 : 제품 변동 분석
  • 동물용 항감염제 시장 규모와 동향 분석(제품별, 2021-2033년)
  • 항균제
    • Cephalosporins
    • Tetracyclines
    • Penicillin
    • Macrolides
    • 기타(Quinoles, sulfonamides, polymyxins)
  • 항진균제
  • 항바이러스제
  • 기타

제6장 동물용 항감염제 시장 : 투여 경로별, 추정 및 동향 분석

  • 부문 대시보드
  • 동물용 항감염제 시장 : 투여 경로별 변동 분석
  • 동물용 항감염제 시장 규모와 동향 분석(투여 경로별, 2021-2033년)
    • 경구
    • 주사
    • 기타

제7장 동물용 항감염제 시장 : 유형별, 추정 및 동향 분석

  • 부문 대시보드
  • 동물용 항감염제 시장 : 유형 변동 분석
  • 동물용 항감염제 시장 규모와 동향 분석(유형별, 2021-2033년)
    • 시판약
    • 처방약

제8장 동물용 항감염제 시장 : 유통 채널별, 추정 및 동향 분석

  • 부문 대시보드
  • 동물용 항감염제 시장 : 유통 채널 변동 분석
  • 동물용 항감염제 시장 규모와 동향 분석(유통 채널별, 2021-2033년)
    • 병원/클리닉 약국
    • 소매 약국
    • E-Commerce

제9장 동물용 항감염제 시장 : 지역별, 추정 및 동향 분석

  • 지역 대시보드
  • 동물용 항감염제 시장 점유율(지역별, 2024년 & 2033년, 100만 달러)
  • 지역 전망
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제10장 경쟁 구도

  • 시장 진출기업 분류
  • 기업 시장 현황 분석/heap 맵 분석
  • 기업 개요
    • Zoetis
    • Boehringer Ingelheim
    • Merck & Co. Inc.
    • Dechra Pharmaceuticals Plc.
    • Elanco Animal Health
    • Ceva Sante Animale
    • Virbac
    • Biogenesis Bago
    • Vetoquinol
    • Calier
    • Norbrook Laboratories
  • 전략 매핑
    • 인수합병(M&A)
    • 파트너십 및 협업
    • 확대
    • 제품 발매
    • 제품 승인
    • 기타
  • 주요 기업 리스트
    • 제조업체 리스트
    • 유통업체 리스트
LSH 25.08.20

Veterinary Anti-infectives Market Summary

The global veterinary anti-infectives market was estimated at USD 8.26 billion in 2024 and is projected to reach USD 14.37 billion by 2033, growing at a CAGR of 6.5% from 2025 to 2033. Key factors expected to drive the market include the rise in animal infectious diseases, developing research initiatives, a boost to prudent antibiotic use, increasing regulatory approvals, and growing applications of Artificial Intelligence (AI).

One of the foremost drivers is the growing integration of artificial intelligence (AI) in veterinary practices. Educational institutions, animal welfare bodies, and commercial players are adopting AI to streamline clinical decision-making, assist in early disease detection, identify treatment gaps, and even accelerate veterinary drug discovery. AI also offers potential for predictive modeling in outbreak surveillance, helping to rationalize anti-infective use amid rising concerns of antimicrobial resistance (AMR).

Another critical factor is the increasing global prevalence of infectious diseases in companion and livestock animals. For example, India-a leading dairy-producing country-witnessed a severe outbreak of Lumpy Skin Disease in 2023, which infected nearly 2.95 million cattle and resulted in over 155,000 deaths across 15 states. Similarly, in the U.S., one of the world's top beef producers, a recent outbreak of highly pathogenic avian influenza (HPAI) among cattle saw over 250 beef samples from 38 states testing positive as of May 2024. South Africa also faced a 30% drop in egg production and had to cull over a million poultry in 2023 due to HPAI. These disease outbreaks are directly escalating the demand for effective anti-infective therapies.

Rising antimicrobial resistance (AMR) is also shaping the market, prompting stricter regulatory surveillance. In June 2025, India's Central Drugs Standard Control Organisation (CDSCO) launched a nationwide initiative to monitor antibiotic use in livestock. It established inter-agency collaborations and mandated AMU (antimicrobial use) data reporting to combat misuse and overuse of antibiotics, which can drive the development and adoption of newer, more targeted anti-infectives.

Intensive R&D and industry collaborations support these regulatory developments. In March 2024, Zoetis partnered with Blacksmith Medicines to develop novel antibiotics to circumvent bacterial resistance by selectively targeting drug-resistant strains. Likewise, discoveries such as bird flu's zoonotic shift to cattle-uncovered by a veterinarian in Texas-open new avenues for therapeutic innovation in livestock disease management.

Additionally, the growth of generic and value-added veterinary medicines is expanding market accessibility. The 2024 European Market Study by Access VetMed revealed that generics account for around 50% of all veterinary product authorizations, with significant traction in anti-infectives and antiparasitics. Despite regulatory burdens like EU Regulation 2019/6, especially for SMEs, the sector remains growing, particularly for companion animal products and alternative administration routes.

Overall, the rise in infectious disease outbreaks, regulatory tightening on antimicrobial use, technological innovations like AI, and increased investment in R&D and generics significantly propel the veterinary anti-infectives market. These forces are expected to meet current treatment demands and ensure veterinary antimicrobial therapy's long-term sustainability and efficacy.

Global Veterinary Anti-infectives Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary anti-infectives market report based on animal type, product, route of administration, type, distribution channel & region.

  • Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Livestock Animal
    • Poultry
    • Swine
    • Cattle
    • Sheep & Goats
    • Fish
    • Others
  • Companion Animal
    • Dogs
    • Cats
    • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Antimicrobial
    • Tetracyclines
    • Penicillin
    • Cephalosporins
    • Macrolides
    • Quinolones
    • Others
  • Antifungals
  • Antivirals
  • Antiparasitic
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
  • Topical
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • Prescription
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital/ Clinic Pharmacy
  • Retail Pharmacies
  • E-commerce
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • India
    • China
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Veterinary Anti-infectives Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rise in Infectious Diseases Among Animals
      • 3.2.1.2. Growing Research Initiatives
      • 3.2.1.3. Boost to Prudent Use of Antibiotics
      • 3.2.1.4. Increasing Regulatory Approvals
      • 3.2.1.5. Growing Applications of AI
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Drop in Consumption
      • 3.2.2.2. Emerging Drug Resistance
      • 3.2.2.3. Stringent Regulations
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Veterinary Anti-infectives Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework by Key Countries
    • 3.3.4. Estimated Animal Population, by Key Species, by Key Countries, 2021-2023
    • 3.3.5. Prevalence of Key Infectious Diseases, by key species, by key countries (2024)
    • 3.3.6. COVID-19 Impact Analysis

Chapter 4. Veterinary Anti-infectives Market: Animal Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Veterinary Anti-infectives Market: Animal type Movement Analysis
  • 4.3. Veterinary Anti-infectives Market Size & Trend Analysis, by animal type, 2021 to 2033 (USD Million)
  • 4.4. Livestock Animal
    • 4.4.1. Production Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Poultry
      • 4.4.2.1. Poultry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Swine
      • 4.4.3.1. Swine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Cattle
      • 4.4.4.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Sheep & Goats
      • 4.4.5.1. Sheep & Goats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.6. Fish
      • 4.4.6.1. Fish Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Companion Animal
    • 4.5.1. Companion Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Dogs
      • 4.5.2.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Cats
      • 4.5.3.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Veterinary Anti-infectives Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Veterinary Anti-infectives Market: Product Movement Analysis
  • 5.3. Veterinary Anti-infectives Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 5.4. Antimicrobials
    • 5.4.1. Antimicrobials Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Cephalosporins
      • 5.4.2.1. Cephalosporins Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Tetracyclines
      • 5.4.3.1. Tetracyclines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Penicillin
      • 5.4.4.1. Penicillin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Macrolides
      • 5.4.5.1. Macrolides Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.6. Others (Quinoles, sulfonamides, polymyxins)
      • 5.4.6.1. Others (Quinoles, sulfonamides, polymyxins) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Antifungals
    • 5.5.1. Antifungals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Antivirals
    • 5.6.1. Antivirals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Veterinary Anti-infectives Market: By Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Veterinary Anti-infectives Market: By Route of Administration Movement Analysis
  • 6.3. Veterinary Anti-infectives Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
    • 6.3.1. Oral
      • 6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Injectables
      • 6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Anti-infectives Market: By Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Veterinary Anti-infectives Market: By Type Movement Analysis
  • 7.3. Veterinary Anti-infectives Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
    • 7.3.1. OTC
      • 7.3.1.1. OTC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Prescription
      • 7.3.2.1. Prescription Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Anti-infectives Market: By Distribution Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Veterinary Anti-infectives Market: By Distribution Channel Movement Analysis
  • 8.3. Veterinary Anti-infectives Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
    • 8.3.1. Hospital/Clinic Pharmacy
      • 8.3.1.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. Retail Pharmacies
      • 8.3.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. E-commerce
      • 8.3.3.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Veterinary Anti-infectives Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Dashboard
  • 9.2. Veterinary Anti-infectives Market Share, By Region, 2024 & 2033, USD Million
  • 9.3. Regional Outlook
  • 9.4. North America
    • 9.4.1. North America Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. U.S. Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Canada Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Mexico Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. UK Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Germany Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. France Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Italy Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Spain Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7. Denmark
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Denmark Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.5.8. Sweden
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Sweden Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.5.9. Norway
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Norway Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Japan Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. China Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. India Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5. Australia
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Australia Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.6.6. South Korea
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. South Korea Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Thailand Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Brazil Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Argentina Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 9.8. Middle East & Africa
    • 9.8.1. Middle East & Africa Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. South Africa Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Saudi Arabia Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. UAE Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Kuwait Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
  • 10.2. Company Market Position Analysis/ Heap Map Analysis
  • 10.3. Company Profiles
    • 10.3.1. Zoetis
      • 10.3.1.1. Participant's Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Product Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Boehringer Ingelheim
      • 10.3.2.1. Participant's Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Product Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Merck & Co. Inc.
      • 10.3.3.1. Participant's Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Product Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Dechra Pharmaceuticals Plc.
      • 10.3.4.1. Participant's Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Product Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Elanco Animal Health
      • 10.3.5.1. Participant's Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Product Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Ceva Sante Animale
      • 10.3.6.1. Participant's Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Product Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Virbac
      • 10.3.7.1. Participant's Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Product Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Biogenesis Bago
      • 10.3.8.1. Participant's Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Product Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Vetoquinol
      • 10.3.9.1. Participant's Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Product Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Calier
      • 10.3.10.1. Participant's Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Product Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Norbrook Laboratories
      • 10.3.11.1. Participant's Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Product Benchmarking
      • 10.3.11.4. Strategic Initiatives
  • 10.4. Strategy Mapping
    • 10.4.1. Mergers & Acquisitions
    • 10.4.2. Partnerships & Collaborations
    • 10.4.3. Expansion
    • 10.4.4. Product launch
    • 10.4.5. Product Approval
    • 10.4.6. Others
  • 10.5. List of Key Companies
    • 10.5.1. List of Manufacturers
    • 10.5.2. List of Distributors
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제